Collins Helen Louise bought ELVN
February 17, 2026 · Form 4 insider transaction
Collins Helen Louise bought 45,000 shares of Enliven Therapeutics, Inc. at $2.48 per share, a transaction worth $111.6K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
45,000
Price
$2.48
Total value
$111.6K
InsiderCollins Helen Louise
RoleOfficer, Director
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateFebruary 17, 2026
Filing dateFebruary 19, 2026
Shares owned after70,000
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.